The company's principal activity is to develop a biochemical technology that will focus on the existing drug therapies. The technology will reduce toxicity and improve efficacy of the existing drug therapies including cancer chemotherapies. In order to achieve that, the technology will combine the drugs with a number of carbohydrate compounds. The fundamental objective of this technology is to increase the body's tolerance to the drugs by enabling delivery of the drugs while protecting the healthy tissue. The company has selected the first group of drugs that include 5-fluorouracil, adriamycin, taxol, cytoxan and cisplatin for the upgradation programs. The company is in the development stage.
Executive Information
Name
Title
Email
David Platt
Chmn., CEO, Pres., Member - Scientific Advisory Board
N/A
Carl Lueders
CFO
N/A
Maureen Foley
COO
N/A
Anthony Squeglia
VP - Investor Relations
N/A
Anatole Klyosov
Chief Scientist, Member - Scientific Advisory Board
